- Home
- PCN vs MYGN Comparison
PCN vs MYGN Comparison
Compare PCN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCN
- MYGN
- Stock Information
- Founded
- PCN 2001
- MYGN 1991
- Country
- PCN United States
- MYGN United States
- Employees
- PCN N/A
- MYGN N/A
- Industry
- PCN Investment Managers
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PCN Finance
- MYGN Health Care
- Exchange
- PCN Nasdaq
- MYGN Nasdaq
- Market Cap
- PCN 810.6M
- MYGN 744.7M
- IPO Year
- PCN N/A
- MYGN 1995
- Fundamental
- Price
- PCN $12.79
- MYGN $4.33
- Analyst Decision
- PCN
- MYGN Hold
- Analyst Count
- PCN 0
- MYGN 16
- Target Price
- PCN N/A
- MYGN $15.47
- AVG Volume (30 Days)
- PCN 218.7K
- MYGN 3.3M
- Earning Date
- PCN 01-01-0001
- MYGN 05-06-2025
- Dividend Yield
- PCN 9.73%
- MYGN N/A
- EPS Growth
- PCN N/A
- MYGN N/A
- EPS
- PCN N/A
- MYGN N/A
- Revenue
- PCN N/A
- MYGN $831,300,000.00
- Revenue This Year
- PCN N/A
- MYGN N/A
- Revenue Next Year
- PCN N/A
- MYGN $6.42
- P/E Ratio
- PCN N/A
- MYGN N/A
- Revenue Growth
- PCN N/A
- MYGN 7.38
- 52 Week Low
- PCN $10.70
- MYGN $3.81
- 52 Week High
- PCN $14.48
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PCN 50.01
- MYGN 33.71
- Support Level
- PCN $12.65
- MYGN $3.99
- Resistance Level
- PCN $12.77
- MYGN $4.38
- Average True Range (ATR)
- PCN 0.09
- MYGN 0.23
- MACD
- PCN 0.01
- MYGN 0.15
- Stochastic Oscillator
- PCN 66.67
- MYGN 55.00
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.